Biopharmaceutical company AntriaBio, Inc. announced Sept. 16 that it has added AB301, a weekly injectable treatment for patients with Type 2 diabetes, to its product candidate line.
AntriaBio specializes in extended-release therapies. AB301 is a combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, AntriaBio's basal insulin lead product candidate.
Initial results of in vitro and in vivo studies
have shown AB301 has the potential to be a well-tolerated, effective therapy for Type 2 diabetes.
"Our extended release platform is extremely versatile, providing us with the flexibility to develop a range of differentiated long-acting injectable therapies," AntriaBio Chief Scientific Officer
Sankaram Mantripragada said. "I am delighted by the team's efforts in successfully formulating a weekly GLP-1 agonist and basal insulin combination, which is a significant milestone in the development of insulin therapies."
Preclinical studies of AB301 are continuing.
"We strongly believe there is a potential advantage of combining a GLP-1 agonist with basal insulin to complement glycemic control while attenuating weight gain and hypoglycemic risk,"
AntriaBio Vice President of Clinical Development
said. "The potential for combination of these two important therapies in a convenient weekly injection is particularly exciting. If we are successful in its development, we are hopeful AB301 can one day become another approach for initiating insulin therapy in patients with Type 2 diabetes."
More information about AB301 or AntriaBio can be found at www.antriabio.com.
AntriaBio adds Type 2 diabetes treatment to product candidate line
Organizations in this Story
Want to get notified whenever we write about AntraBio, Inc. ?
Next time we write about AntraBio, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts